logo
Plus   Neg
Share
Email

Lululemon Athletica Q4 Profit Rises, Does Not Provide Outlook

Lululemon Athletica Inc. (LULU) on Thursday reported a fourth-quarter profit that rose from a year ago, driven largely by strong revenues and gross margin improvement. Earnings for the quarter trumped Wall Street estimates, while revenues also surpassed expectations. Moving ahead, the yoga apparel maker did not provide any outlook due to the ongoing cornonavirus pandemic.

Vancouver-based Lululemon's fourth-quarter profit rose to $298.0 million or $2.28 per share from $218.5 million or $1.65 per share last year. Analysts polled by Thomson Reuters estimated earnings of $2.24 per share.

Revenues for the quarter jumped 20% to $1.40 billion from $1.17 billion last year. Analysts had a consensus revenue estimate of $1.38 billion for the quarter.

Total comparable sales increased 20 percent, with comparable store sales up 9 percent and direct to consumer revenues up 41 percent. Gross margin improved 70 basis points to 58.0 percent.

CEO Calvin McDonald said, "2019 was a strong year for lululemon, as our teams executed against our Power of Three growth plan. We are now navigating an extraordinary environment, which is currently impacting our business. The strength of our brand and strong financial position will help us manage through the day-to-day, while continuing to effectively plan for and invest in our future."

Looking forward, Lululemon did not provide a guidance for fiscal 2020, due to the "impact that COVID-19 is having across the globe."

LULU closed Thursday's trading at $200.80, up $7.18 or $3.71%, on the Nasdaq. The stock, however, slipped $5.80 or 2.89%, in the after-hours trade.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
U.S. retailers Best Buy Co. Inc., Abercrombie & Fitch Co., and Dollar Tree Inc. on Tuesday reported results for the third quarter that surpassed analysts' expectations. The upbeat results indicate that retailers have largely recovered from the impact of the coronavirus pandemic just as the holiday season approaches. The companies have also intensified their focused on digital sales. The U.S. Food and Drug Administration approved the first drug to treat primary hyperoxaluria type 1 (PH1), an ultra-rare genetic disorder which causes recurrent kidney stones and loss of kidney function. Alnylam Pharmaceuticals' Oxlumo (lumasiran) in the form of injection lowers urinary oxalate levels in pediatric and adult patients. The U.S. federal government's General Services Administration or GSA has awarded a five-year federal transportation contract, estimated to be worth up to $810 million, to Uber Technologies Inc. and Lyft Inc., according to multiple reports. Under the contract, the ride-hailing companies would provide services to various public agencies and their around 4 million employees across the nation.
Follow RTT